Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 367

Results For "ENT"

10744 News Found

Pfizer drug candidate shows strong results in tough breast cancer study
Clinical Trials | March 19, 2026

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged


IIT Roorkee unveils cutting-edge molecular medicine facility
R&D | March 19, 2026

IIT Roorkee unveils cutting-edge molecular medicine facility

The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics


Alcon walks away from LENSAR deal after regulatory roadblock
News | March 19, 2026

Alcon walks away from LENSAR deal after regulatory roadblock

At the center of the collapse is opposition from the Federal Trade Commission


Mankind Pharma acquires Rivotril brand for India
News | March 19, 2026

Mankind Pharma acquires Rivotril brand for India

Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions


Lupin Manufacturing Solutions announces expansion of Dabhasa facility
News | March 19, 2026

Lupin Manufacturing Solutions announces expansion of Dabhasa facility

These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions


Strides acquires generic brands from Sandoz to boost Africa business
News | March 19, 2026

Strides acquires generic brands from Sandoz to boost Africa business

The initial consideration for the transaction is US$ 12 million


Zydus, Lupin join forces to expand access to semaglutide in India
News | March 18, 2026

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus


Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
News | March 18, 2026

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025


Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option
News | March 17, 2026

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect